ENSG Class Action Notice: Ensign Group Sued for Securities Fraud After Reports of Patient Neglect and Regulatory Misconduct Lead to Stock Drops — Investors Urged to Contact BFA Law

For best results when printing this announcement, please click on link below: ENSG Class Action Notice: Ensign Group Sued for Securities Fraud After Reports of Patient Neglect and Regulatory Misconduct Lead to Stock Drops — Investors Urged to Contact BFA Law Ensign has been sued for securities fraud after its stock price fell following reports alleging that the company concealed patient neglect, understaffing, manipulated quality and staffing data, improper billing, and an administrator-license rental scheme. Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against The Ensign Group, Inc.

(NASDAQ:ENSG) and certain of the company’s senior executives for securities fraud after significant stock drops resulting from potential violations of the federal securities laws. If you invested in Ensign, you are encouraged to obtain additional information by visiting: Key Details of the Ensign ($ENSG) Class Action: Lead Plaintiff Deadline: December 7, 2026 Alleged Misconduct: Securities fraud alleging Ensign misrepresented that its business model relied on patient neglect, understaffing, manipulated quality and staffing data, improper billing, and an administrator-license rental scheme. S.

District Court for the Central District of California Action: Contact BFA Law to discuss your rights Investors have until December 7, 2026 to ask the Court to be appointed to lead the case. The complaint asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Ensign securities. S. District Court for the Central District of California.

It is captioned Perusek v. , No. 8:26-cv-02963. Why is Ensign Being Sued for Securities Fraud?

Ensign is a healthcare services company that operates skilled nursing, senior living, and rehabilitative care facilities through affiliated providers. The company relies heavily on Medicare and Medicaid reimbursements, making patient care, staffing, billing, and regulatory compliance central to its business model. According to the complaint, Ensign represented that quality patient care was central to its business, described its clinical outcomes and CMS ratings, and characterized regulatory and compliance risks as contingencies.

As alleged, Defendants concealed systematic understaffing and patient neglect, manipulated reported quality and staffing data, engaged in improper Medicare and Medicaid billing and upcoding, and used licensed administrators who did not actually manage certain facilities. Why did Ensign’s Stock Drop? On June 8, 2026, Hunterbrook Media published “Ensign: The Nursing Home Empire Built on Fatal Neglect,” based on a five-month investigation.

The report alleged that Ensign acquired distressed nursing facilities, reduced registered-nurse and other skilled-care hours, used self-reported data to improve quality ratings, and generated profits by providing less care than residents required despite receiving public funds based on patient acuity. 42 per share on June 8, 2026. ” The report alleged that Ensign used licensed administrators who were seldom present and did not actually manage certain facilities, while unlicensed operators handled day-to-day operations.

Muddy Waters estimated that the alleged practices existed at approximately 20% of Ensign’s skilled nursing facilities and could expose Ensign to significant sanctions, slower growth, and reduced margins. 13 per share on June 11, 2026. On June 18, 2026, Hunterbrook published a follow-up report, “New: Patients Hungry in Ensign Facilities,” alleging additional firsthand evidence of resident hunger, inadequate food and supplies, payroll and staffing-data falsification, understaffing, and employees working above their license levels. 65 per share on June 18, 2026.

Click here for more information: What Can You Do? If you invested in Ensign, you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation.

The firm will seek court approval for any potential fees and expenses. 3619 Why Bleichmar Fonti & Auld LLP? BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS, and its attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360, and “SuperLawyers” by Thomson Reuters.

’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd. For more information about BFA and its attorneys, please visit ( ) Attorney advertising. Past results do not guarantee future outcomes.

3619